BioSpace News Archive

I-MED Pharma USA is bringing the world’s most innovative dry eye product portfolio to the U.S. market.

Timber Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, announced the closing of its previously announced underwritten public offering of 23,437,500 shares of its common stock and accompanying warrants to purchase up to an aggregate of 23,437,500 shares of common stock.

QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) and BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that they have reached a settlement in the patent infringement lawsuit related to QIAGEN’s NeuMoDx™ 96 and NeuMoDx™ 288 clinical PCR systems that QIAGEN acquired from NeuMoDx Inc. in 2020.

Atara Biotherapeutics, Inc., a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported the grant of an aggregate of 52,474 restricted stock units of Atara’s common stock to 15 newly hired employees and stock options to purchase an aggregate of 5,618 shares of Atara’s common stock to one such newly hired employee.

Mainz Biomed N.V., a molecular genetics diagnostics company specializing in the early detection of cancer, announced that its common stock commenced trading on the Nasdaq Capital Market today under the ticker symbol MYNZ.

ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) today announced that management will hold its third quarter 2021 earnings call Thursday, November 11, 2021, at 8:30 AM Eastern time.

Castle Biosciences, Inc today announced the publication of a study validating performance of a novel algorithm designed to integrate the DecisionDx®-Melanoma gene expression profile

Biocom California, the association representing the California life science industry, issued the following statement regarding the drug pricing portion in the “Build Back Better” legislation.

Pharmaron Beijing Co., Limited (Stock Code: 300759.SZ/3759.HK) (“Pharmaron”) today announced the promotion of Ms. Katherine Lee to Chief Business Officer, effective October 1, 2021.

Bluestar Genomics today announced the presentation of new analytical performance data on its proprietary non-invasive pancreatic cancer test at the American Pancreatic Association (APA) annual meeting.